D. Boral Capital Cuts Quince Therapeutics (NASDAQ:QNCX) Price Target to $4.00

Quince Therapeutics (NASDAQ:QNCX) had its target price reduced by D. Boral Capital from $12.00 to $4.00 in a report released on Tuesday morning,Benzinga reports. D. Boral Capital currently has a buy rating on the stock.

Several other equities research analysts have also weighed in on the company. Brookline Capital Management started coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price target on the stock. Oppenheimer started coverage on shares of Quince Therapeutics in a research note on Monday. They set an “outperform” rating and a $10.00 target price for the company. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $8.00.

Quince Therapeutics Price Performance

Shares of Quince Therapeutics stock opened at $1.40 on Tuesday. The company has a market cap of $61.60 million, a PE ratio of -1.13 and a beta of 0.71. The business has a 50 day moving average of $1.47 and a 200 day moving average of $1.44. Quince Therapeutics has a 52 week low of $0.51 and a 52 week high of $2.45. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09). The company had revenue of $0.17 million for the quarter. As a group, equities research analysts forecast that Quince Therapeutics will post -1.21 earnings per share for the current year.

Institutional Trading of Quince Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Anfield Capital Management LLC bought a new stake in shares of Quince Therapeutics during the 4th quarter valued at about $50,000. Virtu Financial LLC bought a new position in shares of Quince Therapeutics in the 4th quarter worth approximately $55,000. Two Sigma Investments LP purchased a new position in shares of Quince Therapeutics in the fourth quarter worth approximately $57,000. Northern Trust Corp grew its position in shares of Quince Therapeutics by 48.5% during the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after acquiring an additional 16,501 shares during the period. Finally, Scharf Investments LLC bought a new stake in shares of Quince Therapeutics during the 4th quarter valued at $170,000. Hedge funds and other institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.